How resistant are levodopa-resistant axial symptoms? Response of freezing, posture, and voice to increasing levodopa intestinal infusion rates in Parkinson disease.
Parkinson disease
axial symptoms
freezing of gait
levodopa
posture
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
23
08
2022
received:
09
07
2022
accepted:
01
09
2022
pubmed:
13
9
2022
medline:
17
12
2022
entrez:
12
9
2022
Statut:
ppublish
Résumé
Treatment of freezing of gait (FoG) and other Parkinson disease (PD) axial symptoms is challenging. Systematic assessments of axial symptoms at progressively increasing levodopa doses are lacking. We sought to analyze the resistance to high levodopa doses of FoG, posture, speech, and altered gait features presenting in daily-ON therapeutic condition. We performed a pre-/postinterventional study including patients treated with levodopa/carbidopa intestinal gel infusion (LCIG) with disabling FoG in daily-ON condition. Patients were evaluated at their usual LCIG infusion rate (T1), and 1 h after 1.5× (T2) and 2× (T3) increase of the LCIG infusion rate by quantitative outcome measures. The number of FoG episodes (primary outcome), posture, speech, and gait features were objectively quantified during a standardized test by a blinded rater. Changes in motor symptoms, dyskinesia, and plasma levodopa concentrations were also analyzed. We evaluated 16 patients with a mean age of 69 ± 9.4 years and treated with LCIG for a mean of 2.2 ± 2.1 years. FoG improved in 83.3% of patients by increasing the levodopa doses. The number of FoG episodes significantly decreased (mean = 2.3 at T1, 1.7 at T2, 1.2 at T3; p = 0.013). Posture and speech features did not show significant changes, whereas stride length (p = 0.049), turn duration (p = 0.001), and turn velocity (p = 0.024) significantly improved on doubling the levodopa infusion rate. In a short-term evaluation, the increase of LCIG dose can improve "dopa-resistant" FoG and gait issues in most advanced PD patients with overall good control of motor symptoms in the absence of clinically significant dyskinesia.
Sections du résumé
BACKGROUND AND PURPOSE
Treatment of freezing of gait (FoG) and other Parkinson disease (PD) axial symptoms is challenging. Systematic assessments of axial symptoms at progressively increasing levodopa doses are lacking. We sought to analyze the resistance to high levodopa doses of FoG, posture, speech, and altered gait features presenting in daily-ON therapeutic condition.
METHODS
We performed a pre-/postinterventional study including patients treated with levodopa/carbidopa intestinal gel infusion (LCIG) with disabling FoG in daily-ON condition. Patients were evaluated at their usual LCIG infusion rate (T1), and 1 h after 1.5× (T2) and 2× (T3) increase of the LCIG infusion rate by quantitative outcome measures. The number of FoG episodes (primary outcome), posture, speech, and gait features were objectively quantified during a standardized test by a blinded rater. Changes in motor symptoms, dyskinesia, and plasma levodopa concentrations were also analyzed.
RESULTS
We evaluated 16 patients with a mean age of 69 ± 9.4 years and treated with LCIG for a mean of 2.2 ± 2.1 years. FoG improved in 83.3% of patients by increasing the levodopa doses. The number of FoG episodes significantly decreased (mean = 2.3 at T1, 1.7 at T2, 1.2 at T3; p = 0.013). Posture and speech features did not show significant changes, whereas stride length (p = 0.049), turn duration (p = 0.001), and turn velocity (p = 0.024) significantly improved on doubling the levodopa infusion rate.
CONCLUSIONS
In a short-term evaluation, the increase of LCIG dose can improve "dopa-resistant" FoG and gait issues in most advanced PD patients with overall good control of motor symptoms in the absence of clinically significant dyskinesia.
Identifiants
pubmed: 36093563
doi: 10.1111/ene.15558
pmc: PMC10092343
doi:
Substances chimiques
Levodopa
46627O600J
Antiparkinson Agents
0
Carbidopa
MNX7R8C5VO
Gels
0
Drug Combinations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-106Informations de copyright
© 2022 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Neurol Sci. 2015 Sep;36(9):1683-6
pubmed: 25939726
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
Neurology. 2009 Nov 24;73(21):1738-45
pubmed: 19933974
Mov Disord. 2008;23 Suppl 2:S475-81
pubmed: 18668619
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Gait Posture. 2009 Nov;30(4):459-63
pubmed: 19660949
Mov Disord. 2008 Dec 15;23(16):2398-403
pubmed: 19025759
Lancet Neurol. 2011 Jun;10(6):538-49
pubmed: 21514890
Lancet Neurol. 2011 Aug;10(8):734-44
pubmed: 21777828
Health Inf Sci Syst. 2021 Jul 30;9(1):32
pubmed: 34422258
Front Hum Neurosci. 2021 Nov 02;15:741918
pubmed: 34795568
Mov Disord. 2020 May;35(5):895-896
pubmed: 32167610
Front Neurol. 2017 Aug 22;8:432
pubmed: 28878734
Sensors (Basel). 2021 Apr 10;21(8):
pubmed: 33920070
JAMA Neurol. 2020 Mar 1;77(3):287-288
pubmed: 31841600
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Mov Disord Clin Pract. 2018 Oct 25;5(5):542-545
pubmed: 30515445
Mov Disord. 2008 Mar 15;23(4):574-80
pubmed: 18163453
Front Neurol. 2020 May 12;11:328
pubmed: 32477239
Parkinsonism Relat Disord. 2015 Nov;21(11):1349-54
pubmed: 26439944
Mov Disord. 2011 Mar;26(4):728-30
pubmed: 21506151
Parkinsons Dis. 2019 Jan 02;2019:6505232
pubmed: 30719277
Parkinsonism Relat Disord. 2018 Jul;52:1-5
pubmed: 29907329
Neurology. 2019 May 28;92(22):e2559-e2570
pubmed: 31043471
Parkinsonism Relat Disord. 2016 May;26:10-6
pubmed: 26972527
Nat Rev Neurol. 2015 Feb;11(2):98-110
pubmed: 25582445
J Voice. 2011 Jul;25(4):e199-205
pubmed: 21051196
Parkinsonism Relat Disord. 2015 Jan;21(1):50-4
pubmed: 25466406
Parkinsonism Relat Disord. 2019 May;62:122-127
pubmed: 30638820
J Neurol Sci. 2017 Jun 15;377:179-184
pubmed: 28477691
Mov Disord Clin Pract. 2019 Jun 29;6(7):576-585
pubmed: 31538092
Neurol Sci. 2020 Jul;41(7):1927-1930
pubmed: 32172404
Brain. 2009 Aug;132(Pt 8):2151-60
pubmed: 19433440
Mov Disord. 2021 Apr;36(4):803-814
pubmed: 33373483
Mov Disord. 2016 Dec;31(12):1785-1795
pubmed: 27779784
Eur J Neurol. 2023 Jan;30(1):96-106
pubmed: 36093563
Neurology. 2012 Feb 14;78(7):454-7
pubmed: 22262741
J Neurol Neurosurg Psychiatry. 2016 Jan;87(1):75-85
pubmed: 25896683
J Neural Transm (Vienna). 2010 Feb;117(2):197-205
pubmed: 20012657
Neurology. 2018 Jan 9;90(2):e164-e171
pubmed: 29263221
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
NPJ Parkinsons Dis. 2021 Nov 11;7(1):98
pubmed: 34764299
J Neurol Sci. 2018 Feb 15;385:105-108
pubmed: 29406886
Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345
pubmed: 32258239
Parkinsonism Relat Disord. 2012 Jun;18(5):572-7
pubmed: 22445248
Mov Disord. 2013 May;28(5):668-70
pubmed: 23408503